Plasma glycated CD59, a novel biomarker for the prediction, diagnosis, and follow-up of women with gestational diabetes
Bogdanet, Delia
Bogdanet, Delia
Loading...
Repository DOI
Publication Date
2022-12-06
Type
Thesis
Downloads
Citation
Abstract
The prevalence of gestational diabetes (GDM) is rising worldwide. Plasma glycated CD59 (pGCD59) is an emerging biomarker for the detection of hyperglycaemia. The aim of this study was to explore the ability of pGCD59 to predict and/or identify GDM diagnosed at 24-28 weeks of gestation by a 2h 75g oral glucose tolerance test (OGTT), the ability of pGCD59 to predict post-partum glucose intolerance (GI) diagnosed by a 2h 75 g OGTT and the ability of pGCD59 to predict adverse pregnancy outcomes. This was a prospective study of pregnant women with no prior diagnosis of diabetes. Samples for pGCD59 were collected at the first antenatal appointment (T1), at the time of the OGTT (T2) and post-partum (PP). The ability of pGCD59 to predict a diagnosis of GI was assessed using nonparametric receiver operating characteristic (ROC) curves. This study found that T1 and T2 pGCD59 levels are a fair predictor of GDM status diagnosed by an elevated fasting plasma glucose (FPG) and a very good predictor of GDM status in subjects with very high BMI. Furthermore, this study showed that T1 and T2 levels of pGCD59 can predict the development of early PP GI with fair accuracy and that PP levels of pGCD59 can identify women with PP GI with good accuracy. T1 and T2 pGCD59 levels showed likely potential in predicting the development of adverse pregnancy outcomes. The observations made within this thesis extend the current knowledge on the utility of pGCD59 in pregnancy. Future studies with a focus on investigating the dynamic between pGCD59 levels-GDM and risk factors (ethnicity, high BMI, gestational weight changes etc.) are required to fully explore and validate the true potential of pGCD59. The inclusion of cohorts with a significantly larger number of adverse pregnancy outcomes will potentially substantiate our findings and extend the utility of pGCD59 in clinical practice.
Publisher
NUI Galway